Moderna’s respiratory syncytial virus vaccine candidate for older adults is about 84 percent effective, its phase 3 study showed, and the company said it will seek approval this year.
Read the full post on Becker's Hospital Review - Healthcare News
Moderna's RSV shot 83.7% effective, late-stage trial shows
